UY27705A1 - Compuestos quimicos. - Google Patents

Compuestos quimicos.

Info

Publication number
UY27705A1
UY27705A1 UY27705A UY27705A UY27705A1 UY 27705 A1 UY27705 A1 UY 27705A1 UY 27705 A UY27705 A UY 27705A UY 27705 A UY27705 A UY 27705A UY 27705 A1 UY27705 A1 UY 27705A1
Authority
UY
Uruguay
Prior art keywords
chemical compounds
compounds
medicines
vivo
man
Prior art date
Application number
UY27705A
Other languages
English (en)
Inventor
Jhon Nochilas Newcombe
Andrew Peter Thonas
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of UY27705A1 publication Critical patent/UY27705A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Se describen compuestos de fórmula (I) : en donde R1 ,R2, R3, R4, R5, y p son tal como se definen en la presente y sales farmacéuticamente aceptables y ésteres hidrolizables in vivo. También se describen procesos para su preparación y su utilización como medicamentos, particularmente medicamentos para la producción de un efecto inhibitorio del ciclo celular (anti-proliferación celular) en un animal de sangre caliente, tal como el hombre.
UY27705A 2002-03-09 2003-03-07 Compuestos quimicos. UY27705A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0205693.5A GB0205693D0 (en) 2002-03-09 2002-03-09 Chemical compounds

Publications (1)

Publication Number Publication Date
UY27705A1 true UY27705A1 (es) 2003-10-31

Family

ID=9932723

Family Applications (1)

Application Number Title Priority Date Filing Date
UY27705A UY27705A1 (es) 2002-03-09 2003-03-07 Compuestos quimicos.

Country Status (21)

Country Link
US (1) US7465728B2 (es)
EP (1) EP1487823A1 (es)
JP (2) JP3569524B1 (es)
KR (1) KR20040091114A (es)
CN (1) CN1649863A (es)
AR (1) AR039563A1 (es)
AU (1) AU2003214394A1 (es)
BR (1) BR0308212A (es)
CA (1) CA2478701A1 (es)
GB (1) GB0205693D0 (es)
IL (1) IL163910A0 (es)
IS (1) IS7439A (es)
MX (1) MXPA04008807A (es)
NO (1) NO20043851L (es)
PL (1) PL372703A1 (es)
RU (1) RU2004130440A (es)
TW (1) TW200306838A (es)
UA (1) UA78292C2 (es)
UY (1) UY27705A1 (es)
WO (1) WO2003076436A1 (es)
ZA (1) ZA200406937B (es)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0004887D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0113041D0 (en) 2001-05-30 2001-07-18 Astrazeneca Ab Chemical compounds
GB0205690D0 (en) 2002-03-09 2002-04-24 Astrazeneca Ab Chemical compounds
AU2003208479A1 (en) 2002-03-09 2003-09-22 Astrazeneca Ab 4- imidazolyl substuited pyrimidine derivatives with cdk inhibitiory activity
GB0311274D0 (en) 2003-05-16 2003-06-18 Astrazeneca Ab Chemical compounds
GB0311276D0 (en) 2003-05-16 2003-06-18 Astrazeneca Ab Chemical compounds
TW200528101A (en) 2004-02-03 2005-09-01 Astrazeneca Ab Chemical compounds
GB0504753D0 (en) * 2005-03-08 2005-04-13 Astrazeneca Ab Chemical compounds
KR20080033450A (ko) 2005-07-30 2008-04-16 아스트라제네카 아베 증식성 질환의 치료에 사용하기 위한 이미다졸릴-피리미딘화합물
CA2619731A1 (en) * 2005-08-23 2007-03-01 Ube Industries, Ltd. Process for preparing 1-substituted 5-acylimidazole compounds
US8378096B2 (en) * 2005-09-23 2013-02-19 Janssen Pharmaceutica N.V. Hexahydro-cycloheptapyrazole cannabinoid modulators
US8378117B2 (en) * 2005-09-23 2013-02-19 Janssen Pharmaceutica N.V. Hexahydro-cycloheptapyrazole cannabinoid modulators
UY29827A1 (es) * 2005-10-03 2007-05-31 Astrazeneca Ab 2-amina-pirimidina-4-(2-metil-1-(tetrahidro-2h-piran-4-il)-1-imidazol-5-y1) sustituidas y sus derivados, composiciones farmacéuticas que las contienen, procesos para su preparación y aplicaciones
JP2009510160A (ja) * 2005-10-03 2009-03-12 アストラゼネカ・アクチエボラーグ アルツハイマー病を予防および／または治療するための医薬の製造におけるピリミジン誘導体の使用
TW200811169A (en) * 2006-05-26 2008-03-01 Astrazeneca Ab Chemical compounds
EP2044058B1 (en) 2006-06-21 2010-09-29 AstraZeneca AB Chemical compounds
MX2009000770A (es) * 2006-07-21 2009-01-28 Novartis Ag Formulaciones para eteres de piridilo de bencimidazolilo.
EP2137166B1 (en) 2007-04-24 2012-05-30 Ingenium Pharmaceuticals GmbH 4, 6-disubstituted aminopyrimidine derivatives as inhibitors of protein kinases
US8507511B2 (en) 2007-04-24 2013-08-13 Ingenium Pharmaceuticals Gmbh Inhibitors of protein kinases
US8436007B2 (en) * 2007-04-24 2013-05-07 Ingenium Pharmaceuticals Gmbh Inhibitors of protein kinases
WO2008129071A1 (en) * 2007-04-24 2008-10-30 Ingenium Pharmaceuticals Gmbh Inhibitors of protein kinases
EP2291349A2 (en) 2008-04-14 2011-03-09 The Board of Regents of The University of Texas System Small molecule inhibitors of the pleckstrin homology domain and methods for using same
UA103319C2 (en) 2008-05-06 2013-10-10 Глаксосмитклайн Ллк Thiazole- and oxazole-benzene sulfonamide compounds
AU2010237100A1 (en) * 2009-04-15 2011-10-27 Astrazeneca Ab Imidazole substituted pyrimidines useful in the treatment of glycogen synthase kinase 3 related disorders such as Alzheimer's disease
JP6277195B2 (ja) * 2012-10-18 2018-02-07 バイエル ファーマ アクチエンゲゼルシャフト スルホン基を含んでいる５−フルオロ−ｎ−（ピリジン−２−イル）ピリジン−２−アミン誘導体
US9340532B2 (en) 2012-12-14 2016-05-17 Phusis Therapeutics, Inc. Methods and compositions for inhibiting CNKSR1
US10227356B2 (en) 2015-04-20 2019-03-12 Phusis Therapeutics, Inc. Compounds, compositions and methods for inhibiting CNKSR1
WO2016205806A1 (en) * 2015-06-18 2016-12-22 St. Jude Children's Research Hospital Methods and compositions for the prevention and treatment of hearing loss
WO2019157020A1 (en) 2018-02-06 2019-08-15 The Board Of Trustees Of The University Of Illinois Substituted benzothiophene analogs as selective estrogen receptor degraders
CN110314161A (zh) * 2018-03-30 2019-10-11 潍坊医学院 化合物在制备治疗肿瘤的药物中的用途
CN114981298B (zh) 2019-12-12 2024-08-20 听治疗有限责任公司 用于预防和治疗听力损失的组合物和方法
US11857551B1 (en) 2020-07-10 2024-01-02 Ting Therapeutics Llc Methods for the prevention and treatment of hearing loss
CN115919864B (zh) * 2022-12-02 2024-09-03 中南大学湘雅三医院 唑嘧啶胺类化合物在用于制备治疗ibd药物中的应用

Family Cites Families (111)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4659363A (en) 1983-07-25 1987-04-21 Ciba-Geigy Corporation N-(2-nitrophenyl)-2-aminopyrimidine derivatives, the preparation and use thereof
WO1989009393A1 (en) * 1988-03-24 1989-10-05 Igen, Inc. Luminescent chimeric proteins
US4946956A (en) 1988-09-21 1990-08-07 Uniroyal Chemical Company, Inc. Arylenediamine substituted pyrimidines
HU206337B (en) 1988-12-29 1992-10-28 Mitsui Petrochemical Ind Process for producing pyrimidine derivatives and pharmaceutical compositions
US4983608A (en) 1989-09-05 1991-01-08 Hoechst-Roussell Pharmaceuticals, Inc. N-substituted-4-pyrimidinamines and pyrimidinediamines
US5545618A (en) * 1990-01-24 1996-08-13 Buckley; Douglas I. GLP-1 analogs useful for diabetes treatment
GB9012592D0 (en) 1990-06-06 1990-07-25 Smithkline Beecham Intercredit Compounds
AU658646B2 (en) 1991-05-10 1995-04-27 Rhone-Poulenc Rorer International (Holdings) Inc. Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
US5521184A (en) 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
AU672790B2 (en) * 1992-07-15 1996-10-17 Novartis Ag Variants of parathyroid hormone and its fragments
US5516775A (en) 1992-08-31 1996-05-14 Ciba-Geigy Corporation Further use of pyrimidine derivatives
WO1994007890A1 (en) 1992-10-05 1994-04-14 Ube Industries, Ltd. Pyrimidine compound
US6077822A (en) * 1993-09-14 2000-06-20 Dumex-Alpharma A/S Drug salts
US5612340A (en) 1993-10-01 1997-03-18 Ciba-Geigy Corporation Pyrimidineamine derivatives and processes for the preparation thereof
CZ290681B6 (cs) 1993-10-01 2002-09-11 Novartis Ag N-Fenyl-2-pyrimidinaminové deriváty, způsob jejich výroby, farmaceutické prostředky, které je obsahují a jejich použití
AU693114B2 (en) 1993-10-01 1998-06-25 Novartis Ag Pharmacologically active pyrimidineamine derivatives and processes for the preparation thereof
US5543520A (en) 1993-10-01 1996-08-06 Ciba-Geigy Corporation Pyrimidine derivatives
GB9325217D0 (en) 1993-12-09 1994-02-09 Zeneca Ltd Pyrimidine derivatives
EP0775120B1 (en) 1994-08-13 2003-06-04 Yuhan Corporation Novel pyrimidine derivatives and processes for the preparation thereof
CA2214685C (en) 1995-03-10 2008-05-20 Berlex Laboratories, Inc. Benzamidine derivatives their preparation and their use as anti-coagulants
US5739143A (en) 1995-06-07 1998-04-14 Smithkline Beecham Corporation Imidazole compounds and compositions
IL118544A (en) 1995-06-07 2001-08-08 Smithkline Beecham Corp History of imidazole, the process for their preparation and the pharmaceutical preparations containing them
US6852690B1 (en) * 1995-08-22 2005-02-08 Amylin Pharmaceuticals, Inc. Method and composition for enhanced parenteral nutrition
GB9523675D0 (en) 1995-11-20 1996-01-24 Celltech Therapeutics Ltd Chemical compounds
JP2000511883A (ja) 1996-04-19 2000-09-12 ノボ ノルディスク アクティーゼルスカブ ホスホチロシン認識ユニットを有する分子のモジュレーター
DE19616486C5 (de) * 1996-04-25 2016-06-30 Royalty Pharma Collection Trust Verfahren zur Senkung des Blutglukosespiegels in Säugern
TW440563B (en) 1996-05-23 2001-06-16 Hoffmann La Roche Aryl pyrimidine derivatives and a pharmaceutical composition thereof
AU708883B2 (en) 1996-06-10 1999-08-12 Merck & Co., Inc. Substituted imidazoles having cytokine inhibitory activity
GB9619284D0 (en) 1996-09-16 1996-10-30 Celltech Therapeutics Ltd Chemical compounds
AU5147598A (en) 1996-10-17 1998-05-11 Smithkline Beecham Corporation Methods for reversibly inhibiting myelopoiesis in mammalian tissue
GB9622363D0 (en) 1996-10-28 1997-01-08 Celltech Therapeutics Ltd Chemical compounds
US7091183B1 (en) * 1996-12-03 2006-08-15 Boston Medical Center Corporation Specific antagonists for glucose-dependent insulinotropic polypeptide (GIP)
EP0964864B1 (en) 1997-02-05 2008-04-09 Warner-Lambert Company LLC Pyrido 2,3-d pyrimidines and 4-aminopyrimidines as inhibitors of cellular proliferation
US5846937A (en) * 1997-03-03 1998-12-08 1149336 Ontario Inc. Method of using exendin and GLP-1 to affect the central nervous system
DE19710435A1 (de) 1997-03-13 1998-09-17 Hoechst Ag Verwendung von Pyrimidinderivaten zur Prävention von Krebs allein oder in Kombination mit anderen therapeutischen Maßnahmen
GB9705361D0 (en) 1997-03-14 1997-04-30 Celltech Therapeutics Ltd Chemical compounds
US5998204A (en) * 1997-03-14 1999-12-07 The Regents Of The University Of California Fluorescent protein sensors for detection of analytes
JP2002501532A (ja) 1997-05-30 2002-01-15 メルク エンド カンパニー インコーポレーテッド 新規血管形成阻害薬
CN100443481C (zh) 1997-06-12 2008-12-17 艾文蒂斯药品有限公司 咪唑基-环缩醛类
TW517055B (en) 1997-07-02 2003-01-11 Smithkline Beecham Corp Novel substituted imidazole compounds
WO1999018096A1 (en) 1997-10-02 1999-04-15 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
JP2001519381A (ja) 1997-10-10 2001-10-23 インペリアル・カレッジ・イノベイションズ・リミテッド 子宮収縮管理のためのｃｓａｉｄｔｍ化合物の使用
EP1054004B1 (en) 1997-12-15 2008-07-16 Astellas Pharma Inc. Novel pyrimidine-5-carboxamide derivatives
EP1037639A4 (en) 1997-12-19 2002-04-17 Smithkline Beecham Corp HETEROARYL-SUBSTITUTED IMIDAZOLE COMPOUNDS, THEIR PHARMACEUTICAL COMPOSITIONS AND USES
ATE245641T1 (de) 1998-02-17 2003-08-15 Tularik Inc Antivirale pyrimidinderivate
HU230522B1 (hu) 1998-03-27 2016-10-28 Janssen Pharmaceutica N.V HIV-gátló pirimidinszármazékok
GB9806739D0 (en) 1998-03-28 1998-05-27 Univ Newcastle Ventures Ltd Cyclin dependent kinase inhibitors
EP1107958B1 (en) 1998-08-29 2006-08-16 AstraZeneca AB Pyrimidine compounds
JP2002523497A (ja) 1998-08-29 2002-07-30 アストラゼネカ・アクチエボラーグ ピリミジン化合物
KR20010085824A (ko) 1998-09-18 2001-09-07 스타르크, 카르크 단백질 키나아제 억제제로서의 피롤로피리미딘
KR20010085822A (ko) 1998-09-18 2001-09-07 스타르크, 카르크 키나제 억제제로서의 4-아미노피롤로피리미딘
WO2000020592A1 (en) * 1998-10-07 2000-04-13 Medical College Of Georgia Research Institute, Inc. Glucose-dependent insulinotropic peptide for use as an osteotropic hormone
US6531477B1 (en) 1998-10-13 2003-03-11 Dupont Pharmaceuticals Company 6-substituted pyrazolo [3,4-d] pyrimidin-4-ones useful as cyclin dependent kinase inhibitors
CA2348234A1 (en) 1998-10-29 2000-05-11 Chunjian Liu Compounds derived from an amine nucleus that are inhibitors of impdh enzyme
AU6476599A (en) 1998-11-03 2000-05-22 Novartis Ag Anti-inflammatory 4-phenyl-5-pyrimidinyl-imidazoles
GB9828511D0 (en) 1998-12-24 1999-02-17 Zeneca Ltd Chemical compounds
RU2001124352A (ru) 1999-02-01 2004-02-20 Си Ви Терапьютикс, Инк. (Us) Пуриновые ингибиторы циклин-зависимой киназы 2 и Ikb-альфа
US7745216B2 (en) * 1999-02-10 2010-06-29 Curis, Inc. Methods and reagents for treating glucose metabolic disorders
GB9903762D0 (en) 1999-02-18 1999-04-14 Novartis Ag Organic compounds
GB9905075D0 (en) 1999-03-06 1999-04-28 Zeneca Ltd Chemical compounds
US6627633B2 (en) 1999-03-17 2003-09-30 Albany Molecular Research, Inc. 6-substituted biaryl purine derivatives as potent cyclin/CDK inhibitors and antiproliferative agents
ES2225107T3 (es) * 1999-03-29 2005-03-16 Uutech Limited Analogos del peptido inhibidor gastrico y su uso para el tratamiento de la diabetes.
GB9907658D0 (en) 1999-04-06 1999-05-26 Zeneca Ltd Chemical compounds
US6514500B1 (en) * 1999-10-15 2003-02-04 Conjuchem, Inc. Long lasting synthetic glucagon like peptide {GLP-!}
US6849714B1 (en) * 1999-05-17 2005-02-01 Conjuchem, Inc. Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
GB9914258D0 (en) 1999-06-18 1999-08-18 Celltech Therapeutics Ltd Chemical compounds
GB9924862D0 (en) 1999-10-20 1999-12-22 Celltech Therapeutics Ltd Chemical compounds
JP2003512467A (ja) 1999-10-27 2003-04-02 ノバルティス アクチエンゲゼルシャフト チアゾールおよびイミダゾ（４，５−ｂ）ピリジン化合物ならびにそれらの医薬用途
BR0015532A (pt) 1999-11-22 2002-06-25 Smithkline Beecham Plc Compostos
US7101869B2 (en) 1999-11-30 2006-09-05 Pfizer Inc. 2,4-diaminopyrimidine compounds useful as immunosuppressants
ATE449764T1 (de) 1999-12-28 2009-12-15 Pharmacopeia Inc Cytokine, insbesondere tnf-alpha, hemmer
CA2400447C (en) 2000-02-17 2008-04-22 Amgen Inc. Kinase inhibitors
GB0004886D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0004887D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0004890D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0004888D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
CA2417590C (en) * 2000-05-16 2009-08-11 Sanwa Kagaku Kenkyusho Co., Ltd Prophylactic or ameliorative agent for insulin resistance and/or obesity
GB0016877D0 (en) 2000-07-11 2000-08-30 Astrazeneca Ab Chemical compounds
EP1305338A2 (en) * 2000-08-02 2003-05-02 Theratechnologies Inc. Modified peptides with increased potency
GB0021726D0 (en) * 2000-09-05 2000-10-18 Astrazeneca Ab Chemical compounds
US7129242B2 (en) 2000-12-06 2006-10-31 Signal Pharmaceuticals, Llc Anilinopyrimidine derivatives as JNK pathway inhibitors and compositions and methods related thereto
US7122544B2 (en) 2000-12-06 2006-10-17 Signal Pharmaceuticals, Llc Anilinopyrimidine derivatives as IKK inhibitors and compositions and methods related thereto
GB0103926D0 (en) 2001-02-17 2001-04-04 Astrazeneca Ab Chemical compounds
US7078410B2 (en) 2001-02-20 2006-07-18 Astrazeneca Ab 2-arylamino-pyrimidines for the treatment of GSK3-related disorders
SE0100569D0 (sv) 2001-02-20 2001-02-20 Astrazeneca Ab New compounds
JP4316893B2 (ja) 2001-05-16 2009-08-19 バーテックス ファーマシューティカルズ インコーポレイテッド Ｓｒｃおよび他のプロテインキナーゼのインヒビター
PL367130A1 (en) 2001-05-29 2005-02-21 Schering Aktiengesellschaft Cdk inhibiting pyrimidines, production thereof and their use as medicaments
GB0113041D0 (en) 2001-05-30 2001-07-18 Astrazeneca Ab Chemical compounds
AU2002317377A1 (en) 2001-07-20 2003-03-03 Cancer Research Technology Limited Biphenyl apurinic/apyrimidinic site endonuclease inhibitors to treat cancer
DE60228972D1 (de) * 2001-07-31 2008-10-30 Us Gov Health & Human Serv Glp 1 exendin 4 peptidanaloga und deren verwendungen
US7109204B2 (en) 2001-08-01 2006-09-19 Merck & Co., Inc. Tyrosine kinase inhibitors
US7176278B2 (en) * 2001-08-30 2007-02-13 Biorexis Technology, Inc. Modified transferrin fusion proteins
GB0123589D0 (en) 2001-10-01 2001-11-21 Syngenta Participations Ag Organic compounds
DE60211539T2 (de) 2001-10-05 2006-09-21 Smithkline Beecham Corp. Imidazopyridinderivate zur verwendung bei der behandlung von herpes-vireninfektion
KR20040048920A (ko) 2001-11-01 2004-06-10 얀센 파마슈티카 엔.브이. 글리코겐 신타아제 키나제 3-베타 저해제(ｇｓｋ저해제)로서의 헤테로아릴 아민
PL370480A1 (en) 2001-11-07 2005-05-30 F.Hoffmann-La Roche Ag Aminopyrimidines and pyridines
AU2003208479A1 (en) 2002-03-09 2003-09-22 Astrazeneca Ab 4- imidazolyl substuited pyrimidine derivatives with cdk inhibitiory activity
GB0205688D0 (en) 2002-03-09 2002-04-24 Astrazeneca Ab Chemical compounds
GB0205690D0 (en) 2002-03-09 2002-04-24 Astrazeneca Ab Chemical compounds
US20030232761A1 (en) * 2002-03-28 2003-12-18 Hinke Simon A. Novel analogues of glucose-dependent insulinotropic polypeptide
CA2489323A1 (en) * 2002-06-15 2003-12-24 Enteromed, Inc. Treatment of non-alcoholic fatty liver disease
US7361665B2 (en) 2002-07-09 2008-04-22 Vertex Pharmaceuticals Incorporated Inhibitors of c-Jun N-terminal kinases (JNK) and other protein kinases
GB0226583D0 (en) 2002-11-14 2002-12-18 Cyclacel Ltd Compounds
GB0226582D0 (en) 2002-11-14 2002-12-18 Cyclacel Ltd Anti-viral compounds
WO2004087698A2 (en) 2003-03-25 2004-10-14 Vertex Pharmaceuticals Incorporated Thiazoles useful as inhibitors of protein kinases
EP1605946B1 (en) 2003-03-25 2008-05-28 Vertex Pharmaceuticals Incorporated Thiazoles useful as inhibitors of protein kinases
CN1822851B (zh) * 2003-05-15 2011-04-13 塔夫茨大学信托人 肽和多肽药物的稳定类似物
GB0311276D0 (en) 2003-05-16 2003-06-18 Astrazeneca Ab Chemical compounds
DE10349423A1 (de) 2003-10-16 2005-06-16 Schering Ag Sulfoximinsubstituierte Parimidine als CDK- und/oder VEGF-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel
EP1794134A1 (de) 2004-09-29 2007-06-13 Bayer Schering Pharma Aktiengesellschaft Substituierte 2-anilinopyrimidine als zellzyklus -kinase oder rezeptortyrosin-kinase inhibitoren, deren herstellung und verwendung als arzneimittel
US7799915B2 (en) 2004-10-13 2010-09-21 Wyeth Llc Anilino-pyrimidine analogs

Also Published As

Publication number Publication date
MXPA04008807A (es) 2004-11-26
KR20040091114A (ko) 2004-10-27
RU2004130440A (ru) 2005-05-10
ZA200406937B (en) 2006-02-22
TW200306838A (en) 2003-12-01
WO2003076436A1 (en) 2003-09-18
US20050131000A1 (en) 2005-06-16
CN1649863A (zh) 2005-08-03
IS7439A (is) 2004-09-07
US7465728B2 (en) 2008-12-16
PL372703A1 (en) 2005-07-25
UA78292C2 (en) 2007-03-15
AR039563A1 (es) 2005-02-23
JP2004256550A (ja) 2004-09-16
JP3569524B1 (ja) 2004-09-22
JP2005519135A (ja) 2005-06-30
AU2003214394A1 (en) 2003-09-22
BR0308212A (pt) 2004-12-21
CA2478701A1 (en) 2003-09-18
IL163910A0 (en) 2005-12-18
NO20043851L (no) 2004-09-14
EP1487823A1 (en) 2004-12-22
GB0205693D0 (en) 2002-04-24

Similar Documents

Publication Publication Date Title
UY27705A1 (es) Compuestos quimicos.
UY28733A1 (es) Compuestos quimicos
UY29277A1 (es) Derivados de benzamidas (4(4-(1-isopropil-2-metil-1h-imidazol-5-il)-pirimidin-2-il)amino)sustitudas, composiciones que los contienen, procedimiento de preparación y aplicaciones
UY29826A1 (es) Derivados de pirimidina, sales farmaceuticamente aceptables, esteres de los mismos hidrolisables in vivo, procesos de preparacion y aplicaciones
CY1116885T1 (el) Υποκατεστημενα παραγωγα κυκλοεξυλομεθυλιου
ECSP099451A (es) Compuestos de urea policíclicos antibacterianos
UY29300A1 (es) Compuestos quimicos
BRPI0410025A (pt) derivados de amino-propanol como modulador do receptor de esfingosina-1-fosfato
ECSP10010419A (es) Derivados heterocíclicos de urea y métodos de uso de los mismos-211
TNSN07075A1 (en) Pyrimidine derivatives
TW200617009A (en) Organic compounds
CO6440524A2 (es) Derivados de n-(hetero)aril-pirrolidina de pirazol-4-il-pirrolo[2,3-d]pirimidinas y pirrol-3-il-pirrolo[2,3-d]pirimidinas como inhibidores de la quinasa janus.
MY149648A (en) Carboxylalkylene-phenyl)-phenyl-oxalamides, method for the production thereof, and use of same as a medicament
TNSN07074A1 (en) Pyrimidine derivatives
UY29149A1 (es) Tiazolil-dihidro-indazoles
TW200635921A (en) Organic compounds
JO2734B1 (en) Organic compounds
NO20076333L (no) Anvendelse av thiazolderivater og analoge i behandling av kreft
ATE445593T1 (de) Acetylenderivate
ECSP11011558A (es) Nuevos compuestos químicos.
MY135850A (en) Ring-substituted diphenylazetidinones, process for their preparation, medicaments comprising these compounds and their use
ECSP10010659A (es) Derivados heterocíclicos de la urea y sus métodos de empleo
ATE433969T1 (de) Pyrimidine verbindungen
UY32856A (es) Derivados heterocíclicos de urea y métodos de uso de los mismos
EA200601845A1 (ru) НОВЫЕ β-АГОНИСТЫ, СПОСОБ ИХ ПОЛУЧЕНИЯ И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ ЛЕКАРСТВЕННЫХ СРЕДСТВ

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20150520